Liposarcomas: morphological subtypes, prognostic factors and therapeutic options


Cite item

Full Text

Abstract

The article shows the literature review of the biology, prognostic factors and the results of liposarcomas treatment according to the histological subtypes and the localization of the primary tumor. We are also discussing the modern options of systemic therapy, including the original chemotherapy regimens, developed in N.N.Blokhin Russian Cancer Research Center, and new effective therapeutic agents.

About the authors

A A Fedenko

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

Email: fedenko@eesg.ru
д-р мед. наук, ст. науч. сотр. отд-ния химиотерапии НИИ клинической онкологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

References

  1. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Под ред. М.И.Давыдова. М., 2014.
  2. Gadgeel S.M, Harlan L.C, Zeruto C.A et al. Patterns of care in a population - based sample of soft tissue sarcoma patients in the United States. Cancer 2009; 115 (12): 2744-54.
  3. Kindblom L.G, Angervall L, Svendsen P. Liposarcoma: a clinicopathologic, radio - graphic and prognostic study. Acta Pathol Microbiol Scand (Suppl.) 1975; 253: 1-71.
  4. Crago A.M, Singer S. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol 2011; 23 (4): 373-8. http://dx.doi.org/10.1097/CCO.0b013e32834796e6
  5. Evans H.L. Liposarcoma: a study of 55 cases with reassessment of its classification. Am J Surg Pathol 1979; 3 (6): 507-23.
  6. Fletcher C.D. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press, 2002; p. 120-5.
  7. Fletcher C.D. WHO classification of tumours ofsoft tissue and bone. 4th ed. WHO Press, 2013.
  8. Kilpatrick S.E, Doyon J, Choong P.F et al. The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer 1996; 77 (8): 1450-8.
  9. Weiss S.W, Rao V.K. Well - differentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum, and miscellaneous sites. Am J Surg Pathol 1992; 16 (11): 1051-8.
  10. Gebhard S, Coindre J.M, Michels J.J et al. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow - up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 2002; 26 (5): 601-16.
  11. Henricks W.H, Chu Y.C, Goldblum J.R et al. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 1997; 21 (3): 271-81.
  12. Hornick J.L, Bosenberg M.W, Mentzel T et al. Pleomorphic liposarcoma. Am J Surg Pathol 2004; 28 (10): 1257-67. http://dx.doi.org/10. 1097/01.pas.0000135524.73447.4a
  13. Canter R.J, Qin L.X, Ferrone C.R et al. Why do patients with low - grade soft tissuesarcoma die? Ann Surg Oncol 2008; 15 (12): 3550-60. http://dx.doi.org/10.1245/si 0434-008-0163-0
  14. Binh M, Sastre-Garau X, Guillou L et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well - differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms. Am J Surg Pathol 2005; 29 (10): 1340-7.
  15. Fletcher C.D, Akerman M, Dal Cin P et al. Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Am J Pathol 1996; 148 (2): 623-30.
  16. Pedeutour F.A, Forus, Coindre J.M et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes. Cancer 1999; 24 (1): 30-41.
  17. Antonescu C.R, Tschernynvsky S.J, Docuseara R et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript slructure, and histological grade in myxoidliposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 2001; 7: 3977-87.
  18. Aman P.D, Ron, Mandahl N et al. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12; 16)(q 13;p 11). Genes Chromosomes Cancer 1992; 5 (4): 278-85.
  19. Knight J.C, Renwick P.J, Cin P.D et al. Translocation t(12; 16)(q 13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res 1995; 55: 24-7.
  20. Rabbitts T.H, Forster A, Larson R et al. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12; 16) in malignant liposarcoma. Nat Genet 1993; 4 (2): 175-80.
  21. Ron D, Habener J.F. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant - negative inhibitor of gene transcription. Genes Dev 1992; 6 (3): 439-53.
  22. Powers C.A, Mathur M, Raaka B.M et al. Is a high - affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol Endocrinol 1998; 12 (1): 4-18.
  23. Kuroda M, Ishida T, Takanashi M et al. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol 1997; 151 (3): 735-44.
  24. Downes K.A, Goldblum J.R, Montgomery E.A et al. Pleomorphic liposarcoma: a clinicopathologic analysis of 19 cases. Mod Pathol 2001; 14 (3): 179-84.
  25. Mertens F, Fletcher C.D, Dal Cin P et al. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study GrouP. Chromosomes and Morphology. Genes Chromosomes Cancer 1998; 22 (1): 16-25.
  26. Schneider-Stock R, Walter H, Radig K et al. MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas. J Cancer Res Clin Oncol 1998; 124: 532-40.
  27. Fayette J, Martin E, Piperno-Neumann S et al. Angiosarcoma: a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol 2007; 18: 2030-6.
  28. Singer S, Antonescu C.R, Riedel E et al. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003; 238 (3): 358-70. http://dx. doi.org/10.1097/01.sla.0000086542. 11899.38 [discussion: 370-1]
  29. Schwab J.H, Boland P.J, Antonescu C et al. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer 2007; 110 (8): 1815-22. http://dx.doi.Org/10.1002/ cncr.22992
  30. Mc Cormick D, Mentzel T, Beham A et al. Dedifferentiated liposarcoma: clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am J Surg Pathol 1994; 18 (12): 1213-23.
  31. Murphey M.D, Arcara L.K, Fanburg-Smith J. Imaging of musculoskeletal liposarcoma with radiologic - pathologic correlation. Radiographics 2005; 25 (5): 1371-95.
  32. Engstrom K, Bergh P, Gustafson P et al. Liposarcoma: outcome based on the Scandinavian Sarcoma Group register. Cancer 2008; 113 (7): 1649-56. http://dx.doi.org/10.1002/cncr.23784
  33. Kim H.S, Lee J, Yi S.Y et al. Liposarcoma: exploration of clinical prognostic fan tors for risk based stratification of therapy. BMC Cancer 2009; 9: 205. http://dx, doi.org/10.1186/1471-2407-9-205
  34. Linehan D.C, Lewis J.J, Leung D et al. Influence of biologic factors and anatomic site in completely resected liposarcoma. J Clin Oncol 2000; 18 (8): 1637-43.
  35. Lucas D.R, Nascimento A.G, Sanjay B.K et al. Well - differentiated liposarcoma. The Mayo Clinic experience with 58 cases. Am J Clin Pathol 1994; 102 (5): 677-83.
  36. Moreau L.C, Turcotte R, Ferguson P et al. Myxoid/round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases. Ann Surg Oncol 2012; 19 (4): 1081-8. http://dx.doi.org/10.1245/ s10434-011-2127-z
  37. Ghert M.A, Abudu A, Driver N et al. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann Surg Oncol 2005; 12 (1): 10-7. http://dx.doi.org/10.1245/ASO.2005.03.097
  38. Liu C.Y, Yen C.C, Chen W.M et al. Soft tissue sarcoma of extremities: the prognostic significance of adequate surgical margins in primary operation and reoperation after recurrence. Ann Surg Oncol 2010; 17 (8): 2102-11. http://dx.doi.org/ 10.1245/s 10434-010-0997-0
  39. Mc Kee M.D, Liu D.F, Brooks J.J et al. The prognostic significance of margin width for extremity and trunk sarcoma. J Surg Oncol 2004; 85 (2): 68-76. http://dx.doi. org/10.1002/jso.20009
  40. Rosenberg S.A, Tepper J, Glatstein E et al. The treatment of soft - tissue sarcomas of the extremities: prospective randomized evaluation of (1) limb sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982; 196 (3): 305-14.
  41. O’Sullivan B, Davis A.M, Turcotte R et al. Preoperative versus postoperative radiotherapy in soft - tissue sarcoma of the limbs: a randomized trial. Lancet 2002; 359 (9325): 2235-41. http://dx.doi.org/ 10.1016/S0140-6736(02)09292-9
  42. Bonvalot S, Miceli R, Borselli M et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high - volume centers is safe and is associated with Henze & Bauer improved local control. Ann Surg Oncol 2010; 17 (6): 1507-14. http://dx.doi.org/10.1245/s 10434-010-1057-5
  43. Eilber F.C, Eilber F.R, Eckardt J et al. The impact of chemotherapy on the survival of patients with high - grade primary extremity liposarcoma. Ann Surg 2004; 240 (4): 686-97. http://dx.doi.org/10.1097/ 01.sla.0000141710.74073.0d
  44. Gronchi A, Vullo S.Lo, Fiore M et al. Aggressive surgical policies in a retrospectively reviewed single - institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol 2009; 27 (1): 24-30. http://dx.doi.org/10.1200/JCO.2008.17.8871
  45. Lewis J.J, Leung D, Woodruff J.M et al. Retroperitoneal soft - tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998; 228 (3): 355-65.
  46. Pervaiz N, Colterjohn N, Farrokhyar F et al. A systematic meta - analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft - tissue sarcoma. Cancer 2008; 113 (3): 573-81. http://dx.doi.org/10.1002/ cncr.23592
  47. Woll P.J, Reichardt P, Le Cesne A et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft - tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012; 13: 1045-54.
  48. De Laney T.F, Spiro I.J, Suit H.D et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft - tissue sarcomas. Int J Radiat Oncol Biol Phys 2003; 56 (4): 1117-27. http://dx.doi.org/10.1016/ S0360-3016(03)00186-X
  49. Gortzak E, Azzarelli A, Buesa J et al. A randomized phase II study on neoadjuvant chemotherapy for "high - risk" adult soft - tissue sarcoma. Eur J Cancer 2001; 37 (9): 1096-103.
  50. Gronchi A, Bui B.N, Bonvalot S et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 2012; 23 (3): 771-6. doi: 10.1093/annonc/ mdr265. Epub 2011.
  51. Kraybill W.G, Harris J, Spiro I.J et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high - risk, high - grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol 2006; 24 (4): 619-25. http://dx.doi.org/10.1200/JC0.2005.02.5577
  52. Kraybill W.G, Harris J, Spiro I.J et al. Long - term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high - risk, high - grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer 2010; 116 (19): 4613-21. http://dx.doi.org/10.1002/ cncr.25350
  53. Italiano A, Toulmonde M, Cioffi A et al. Advanced well - differentiated dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol 2012; 23 (6): 1601-7. http://dx.doi.org/10.1093/annonc/mdr485
  54. Jennings T.A, Peterson L, Axiotis C.A et al. Angiosarcoma associated with foreign body material: a report of three cases. Cancer 1988; 62 (11): 2436-44.
  55. Jones R.L, Fisher C, Al-Muderis O et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 2005; 41 (18): 2853-60. http://dx.doi.org/10.1016/j.ejca.2005.07.023
  56. Nielsen O.S, Judson I, van Hoesel О et al. Effect of high - dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000; 36 (1): 61-7.
  57. Patel S.R, Vadhan-Raj S, Papadopolous N et al. High - dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies - dose - response and schedule dependence. J Clin Oncol 1997; 15: 2378-84.
  58. Феденко A.A. Модификация режимов химиотерапии сарком мягких тканей. Старые препараты и новые возможности. Саркомы костей, мягких тканей и опухоли кожи. 2015; 4: 3-20.
  59. Demetri G.D, Chawla S.P, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27 (25): 4188-96; doi: 10.1200/JCO.2008. 21.0088. Epub 2009.
  60. Baldini E.H, Goldberg J, Jenner C et al. Long - term outcomes after function - sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 1999; 17 (10): 3252-9.
  61. Grosso F, Jones R.L, Demetri G.D et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8 (7): 595-602. http://dx.doi.org/ 10.1016/S1470-2045(07)70175-4
  62. Hoiczyk M, Grabellus F, Podleska L et al. Trabectedin in metastatic soft tissue sarcomas: role of pretreatment and age. Ann Oncol 2013; 43: 23-8. http://dx.doi. org/10.3892/ijo.2013.1928
  63. Samuels B.L, Chawla S, Patel S et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol 2013; 24 (6): 1703-9. http://dx.doi.org/10.1093/annonc/mds659
  64. Demetri G.D, von Mehren M et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 2016; 34: 786-93.
  65. Феденко А.А. Стратегия лекарственного лечения сарком мягких тканей. Дис. … д - ра мед. наук. М., 2016
  66. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer - soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27 (19): 3126-32; doi: 10.1200/JCO.2008.21.3223. Epub 2009.
  67. Cortes J et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open - label randomised study. Lancet 2011; 377 (9769): 914-23.
  68. Kaufman P.A et al. Phase III open - label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015; 33 (6): 594-601.
  69. Инструкция по медицинскому применению препарата Халавен®: РУ ЛП-001782 от 24.07.2012, с изменениями от 15.06.2016.
  70. Yoshida T, Ozawa Y, Kimura T et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial - mesenchymal transition (EMT) to mesenchymal - epithelial transition (MET) states. Br J Cancer 2014; 110: 1497-505.
  71. Kawano S, Asano M et al. Antimitotic and non - mitotic effects of eribulin mesilate in soft tissue sarcoma. Anticancer Res 2016; 36: 1553-61.
  72. Schöffski P, Ray-Coquard I.L, Cioffi A et al. Activity of eribulin mesylate in patients with soft - tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 2011; 12: 1045-52.
  73. Schöffski P, Chawla S et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open - label, multicentre, phase 3 trial. Lancet 2016; 387 (10028): 1629-37.
  74. Driscoll J.J, Rixe O. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. Cancer J 2009; 15: 401-5.
  75. Chawla S, Schöffski P, Grignani G et al. Subtype - specific Activity in Liposarcoma Patients From a Phase 3, Open - label, Randomized Study of Eribulin Versus Dacarbazine in Patients With Advanced Liposarcoma or Leiomyosarcoma. Poster No. 163. Presented at the ASCO, June 3-7, 2016; Chicago, Illinois.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».